1 / 9

Optogenetic Neurostimulation

Optogenetic Neurostimulation. Revolutionizing Outcomes for Refractory Psychiatric Disorders. Team Bambara. More than 50 % of Parkinson’s patients cannot be effectively treated with pharmaceuticals. Treatment resistant psychiatric disorders have a large patient population.

tallis
Télécharger la présentation

Optogenetic Neurostimulation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Optogenetic Neurostimulation Revolutionizing Outcomes for Refractory Psychiatric Disorders Team Bambara

  2. More than 50 % of Parkinson’s patients cannot be effectively treated with pharmaceuticals

  3. Treatment resistant psychiatric disorders have a large patient population REFRACTORY PARKINSON’S AND ESSENTIAL TREMOR: 5.5 MILLION REFRACTORY DEPRESSION: 4 MIILLION REFRACTORY EPILESPY: 1 MILLION

  4. Electrical Neurostimulation Devices: a close analog Large revenue High growth • Significant limitations • Limited efficacy • Severe side effects

  5. Optogenetic neurostimulation directly addresses these two main limitations “With its high specificity, optogenetics offers higher efficacy and fewer side effects… Neurosurgeons’ primary criteria for purchasing a device are efficacy, side effects, and reimbursement.” -Dr. Raag Airan Neurosurgeon at Johns Hopkins University

  6. Optogenetic Neurostimulation 1. Algae 2. Gene therapy Light-sensitive genes are extracted Genes are added to patient’s DNA 4. Device Mediated Brain Management Turn genes on/off with lights Control neuron activation Fiber optic cable is implanted in the brain 5. A Better Life 3. Surgery

  7. Business Model Technology Licensing: OTL Licensers: Biotech Companies IP IP $$$ IP Purchasing Decision: Neurosurgeons $$$ Capital Equipment & Disposables Device Manufacturing, Distribution, and Sales: Medtronic $$$ Care Providers: Hospitals Care $$$ Payers: Medicare/Medicaid Private Insurance End Users: Patients

  8. Major Risks Medicare/Medicaid Coverage Efficacy in humans • Gene Therapy • Safety • Regulatory approval • Market adoption Capital “We don’t yet know how to control expression for optogenetics gene therapy or if it will be safe.” -Dr. Polina Anikeeva Stanford Optogenetics Researcher

  9. Pivot: apply optogenetics to screening of novel pharmaceuticals “More than 10% of the pharmaceutical screening market is for neural drugs… Patch clamp technology for neural screening is currently too unreliable.” -Dr. Solow-Cordero Manager of Stanford High-Throughput Bioscience Center

More Related